Brean Murray maintains a 'Buy' on Nektar Therapeutics (Nasdaq: NKTR), raises price target from $15 to $20.

Brean analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE